Scrip
Daiichi Sankyo's edoxaban enters pivotal trial for VTE
04 February 2010
Ian Haydock
Please Login to read the full article.
04 February 2010
Ian Haydock
ian.haydock@informa.com
Daiichi Sankyo has begun recruiting for a key Phase III multinational clinical trial programme for its oral direct Factor Xa inhibitor, edoxaban.
The pivotal HOKUSAI VTE study will compare the anticoagulant with standard of care warfarin in the prevention of recurrent venous thromboembolic...
Please Login to read the full article.
RELATED CONTENT
NEWS
- First filing for edoxaban, for orthopaedic surgery uses in Japan
- Daiichi Sankyo's edoxaban shows Phase III promise in orthopaedic setting
- Bayer's anticoagulant rivaroxaban non-inferior to standard therapy in Phase III DVT trial
- Xarelto stumbles on filing update but shines in long-term treatment for VTE risk reduction
FEATURES
Other Informa Features
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
